Tango Therapeutics, Inc. (TNGX)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 137
- Market Cap
- $4.4B
About Tango Therapeutics, Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
SentiSense also tracks daily options readings for Tango Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Tango Therapeutics, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.